Download Files:

Lenalidomide-C5-NH2 (hydrochloride)

SKU HY-122725B-100 mg Category Tags , ,

$400$950

Products Details

Product Description

– Lenalidomide-C5-NH2 hydrochloride is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs, such as MDM2 PROTAC degrader[1][2].

Web ID

– HY-122725B

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture)

Shipping

– Room Temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C18H24ClN3O3

References

– [1]Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481.|[2]Yangbing Li, et al. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. J Med Chem. 2019 Jan 24;62(2):448-466.

CAS Number

– 2595367-27-2

Molecular Weight

– 365.85

Compound Purity

– 98.44

SMILES

– O=C1C(C=CC=C2CCCCCN)=C2CN1C3C(NC(CC3)=O)=O.Cl

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– DMSO : 50 mg/mL (ultrasonic)

Target

– E3 Ligase Ligand-Linker Conjugates

Isoform

– Cereblon

Pathway

– PROTAC

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.